Given its role in cancer cell survival and adaptation, PERK is considered a potential therapeutic target. Inhibitors of PERK are being investigated for their ability to induce cancer cell death by exacerbating ER stress. For instance, drugs that inhibit PERK kinase activity have been shown to reduce tumor growth and enhance the efficacy of chemotherapy in preclinical models. However, targeting PERK must be approached with caution due to its essential roles in normal cellular functions and potential side effects.
